Almirall completes deal with AstraZeneca in respiratory disease

04-Nov-2014 - Spain

Almirall announced that, effective November 1st, it has completed the transaction to transfer to AstraZeneca the rights of Almirall’s respiratory franchise after all closing conditions have been satisfied. AstraZeneca will now own the rights for the development and commercialization of Almirall’s existing proprietary respiratory business, including rights to revenues from Almirall’s partnerships, as well as its pipeline of investigational novel therapies. The franchise includes Eklira® (aclidinium); Duaklir®, the combination of aclidinium with formoterol (LAMA/LABA) that has received a positive opinion from the CHMP in the EU and is being developed in the US; LAS100977 (abediterol), a once-daily long-acting beta2-agonist (LABA) in Phase II; an M3 antagonist beta2-agonist (MABA) platform in pre-clinical development (LAS191351, LAS194871) and Phase I (LAS190792); and multiple pre-clinical programmes. Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, also transfers to AstraZeneca.

Almirall announced this strategic transaction on July 30th, which includes an upfront cash consideration upon completion of $875 million and, additionally, up to $1.22 billion related to development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances